| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pulmonary Disease, Chronic Obstructive | 165 | 2025 | 628 | 31.820 |
Why?
|
| Asthma | 140 | 2025 | 773 | 25.840 |
Why?
|
| Anti-Asthmatic Agents | 58 | 2025 | 118 | 14.260 |
Why?
|
| Bronchodilator Agents | 71 | 2025 | 150 | 13.160 |
Why?
|
| Adrenal Cortex Hormones | 37 | 2025 | 337 | 4.820 |
Why?
|
| Adrenergic beta-2 Receptor Agonists | 25 | 2024 | 51 | 4.530 |
Why?
|
| Forced Expiratory Volume | 54 | 2025 | 173 | 4.290 |
Why?
|
| Quality of Life | 47 | 2025 | 2161 | 4.290 |
Why?
|
| Eosinophils | 18 | 2025 | 122 | 3.790 |
Why?
|
| Administration, Inhalation | 47 | 2025 | 190 | 3.660 |
Why?
|
| Lung | 31 | 2025 | 1556 | 3.600 |
Why?
|
| Adrenergic beta-Agonists | 20 | 2020 | 78 | 3.210 |
Why?
|
| Antibodies, Monoclonal, Humanized | 24 | 2025 | 559 | 3.140 |
Why?
|
| Omalizumab | 16 | 2024 | 35 | 3.040 |
Why?
|
| Exercise Tolerance | 9 | 2025 | 87 | 2.960 |
Why?
|
| Formoterol Fumarate | 19 | 2025 | 29 | 2.820 |
Why?
|
| Biological Products | 16 | 2025 | 137 | 2.760 |
Why?
|
| Anxiety | 13 | 2024 | 1001 | 2.660 |
Why?
|
| Dyspnea | 17 | 2025 | 160 | 2.460 |
Why?
|
| Albuterol | 19 | 2018 | 49 | 2.450 |
Why?
|
| Humans | 305 | 2025 | 132247 | 2.440 |
Why?
|
| Double-Blind Method | 46 | 2025 | 1653 | 2.410 |
Why?
|
| Muscarinic Antagonists | 12 | 2024 | 35 | 2.270 |
Why?
|
| Severity of Illness Index | 49 | 2025 | 3093 | 2.210 |
Why?
|
| Depression | 15 | 2022 | 1350 | 2.210 |
Why?
|
| Anti-Inflammatory Agents | 11 | 2023 | 305 | 2.200 |
Why?
|
| Drug Therapy, Combination | 28 | 2025 | 1177 | 2.180 |
Why?
|
| Chlorobenzenes | 10 | 2024 | 10 | 2.150 |
Why?
|
| Respiratory Function Tests | 22 | 2025 | 212 | 2.120 |
Why?
|
| Benzyl Alcohols | 9 | 2024 | 14 | 2.090 |
Why?
|
| Treatment Outcome | 66 | 2025 | 13027 | 1.840 |
Why?
|
| Cost of Illness | 6 | 2025 | 286 | 1.800 |
Why?
|
| Aged | 90 | 2025 | 21482 | 1.770 |
Why?
|
| Th2 Cells | 7 | 2021 | 188 | 1.770 |
Why?
|
| Nebulizers and Vaporizers | 24 | 2023 | 59 | 1.760 |
Why?
|
| Pneumonia | 6 | 2023 | 333 | 1.730 |
Why?
|
| Fluticasone-Salmeterol Drug Combination | 5 | 2025 | 9 | 1.720 |
Why?
|
| Androstadienes | 12 | 2024 | 52 | 1.700 |
Why?
|
| Ethanolamines | 12 | 2014 | 25 | 1.650 |
Why?
|
| Glycopyrrolate | 5 | 2024 | 10 | 1.640 |
Why?
|
| Status Asthmaticus | 3 | 2023 | 22 | 1.630 |
Why?
|
| Disease Progression | 30 | 2025 | 2233 | 1.610 |
Why?
|
| Scopolamine Derivatives | 5 | 2013 | 11 | 1.510 |
Why?
|
| Middle Aged | 107 | 2025 | 29021 | 1.510 |
Why?
|
| Biomarkers | 29 | 2025 | 3404 | 1.500 |
Why?
|
| Drug Combinations | 17 | 2025 | 280 | 1.450 |
Why?
|
| Comorbidity | 28 | 2025 | 1610 | 1.430 |
Why?
|
| Immunoglobulin E | 15 | 2025 | 180 | 1.350 |
Why?
|
| Budesonide | 4 | 2025 | 19 | 1.350 |
Why?
|
| Quinuclidines | 6 | 2024 | 8 | 1.340 |
Why?
|
| Antibodies, Anti-Idiotypic | 6 | 2018 | 41 | 1.340 |
Why?
|
| Male | 126 | 2025 | 65014 | 1.310 |
Why?
|
| Interleukin-5 | 4 | 2019 | 48 | 1.280 |
Why?
|
| Glucocorticoids | 9 | 2021 | 387 | 1.260 |
Why?
|
| Vital Capacity | 15 | 2025 | 86 | 1.230 |
Why?
|
| Tiotropium Bromide | 9 | 2024 | 14 | 1.220 |
Why?
|
| Smoking | 19 | 2025 | 940 | 1.220 |
Why?
|
| Female | 124 | 2025 | 70787 | 1.210 |
Why?
|
| Primary Health Care | 6 | 2025 | 801 | 1.210 |
Why?
|
| Nitric Oxide | 13 | 2025 | 470 | 1.180 |
Why?
|
| Eosinophilia | 3 | 2023 | 105 | 1.160 |
Why?
|
| Inflammation | 20 | 2025 | 1522 | 1.090 |
Why?
|
| Cell Adhesion Molecules | 6 | 2019 | 234 | 1.070 |
Why?
|
| Airway Obstruction | 5 | 2024 | 167 | 1.070 |
Why?
|
| Phosphodiesterase Inhibitors | 5 | 2019 | 53 | 1.050 |
Why?
|
| Pulmonary Emphysema | 5 | 2025 | 94 | 1.050 |
Why?
|
| Antibodies, Monoclonal | 8 | 2024 | 1036 | 1.040 |
Why?
|
| Budesonide, Formoterol Fumarate Drug Combination | 2 | 2025 | 3 | 1.030 |
Why?
|
| Surveys and Questionnaires | 18 | 2024 | 3995 | 1.020 |
Why?
|
| Spirometry | 19 | 2025 | 75 | 1.010 |
Why?
|
| Cardiovascular Diseases | 5 | 2024 | 2087 | 0.970 |
Why?
|
| Adult | 70 | 2025 | 31614 | 0.960 |
Why?
|
| Influenza, Human | 5 | 2023 | 700 | 0.940 |
Why?
|
| Metered Dose Inhalers | 7 | 2020 | 12 | 0.890 |
Why?
|
| Bronchitis, Chronic | 3 | 2025 | 19 | 0.880 |
Why?
|
| Disease Management | 8 | 2024 | 565 | 0.850 |
Why?
|
| Patient-Centered Care | 4 | 2020 | 237 | 0.840 |
Why?
|
| Exercise | 2 | 2020 | 860 | 0.830 |
Why?
|
| Phenotype | 18 | 2024 | 4540 | 0.810 |
Why?
|
| Molecular Targeted Therapy | 5 | 2020 | 403 | 0.800 |
Why?
|
| Cholinergic Antagonists | 4 | 2015 | 46 | 0.790 |
Why?
|
| Leukotriene Antagonists | 3 | 2023 | 18 | 0.740 |
Why?
|
| Propofol | 1 | 2022 | 50 | 0.730 |
Why?
|
| United States | 33 | 2025 | 11669 | 0.710 |
Why?
|
| Symptom Flare Up | 2 | 2020 | 24 | 0.710 |
Why?
|
| Hospitalists | 1 | 2021 | 47 | 0.700 |
Why?
|
| Anti-Allergic Agents | 4 | 2020 | 27 | 0.690 |
Why?
|
| Hospitalization | 14 | 2025 | 1902 | 0.680 |
Why?
|
| Pharmaceutical Preparations | 1 | 2021 | 89 | 0.670 |
Why?
|
| Precision Medicine | 7 | 2025 | 360 | 0.660 |
Why?
|
| Health Knowledge, Attitudes, Practice | 8 | 2020 | 899 | 0.660 |
Why?
|
| Exercise Therapy | 3 | 2020 | 183 | 0.660 |
Why?
|
| Anti-Bacterial Agents | 3 | 2023 | 2552 | 0.650 |
Why?
|
| Prevalence | 14 | 2023 | 2664 | 0.640 |
Why?
|
| Hypersensitivity | 4 | 2023 | 196 | 0.630 |
Why?
|
| Interleukin-5 Receptor alpha Subunit | 1 | 2019 | 1 | 0.620 |
Why?
|
| Interleukin-4 Receptor alpha Subunit | 1 | 2019 | 9 | 0.610 |
Why?
|
| Nadolol | 2 | 2010 | 12 | 0.610 |
Why?
|
| Prostaglandin Antagonists | 1 | 2019 | 1 | 0.610 |
Why?
|
| Receptors, Prostaglandin | 1 | 2019 | 14 | 0.600 |
Why?
|
| Glucose | 2 | 2021 | 871 | 0.570 |
Why?
|
| Triglycerides | 1 | 2021 | 617 | 0.570 |
Why?
|
| Ketamine | 1 | 2022 | 226 | 0.560 |
Why?
|
| Receptors, Immunologic | 1 | 2019 | 127 | 0.560 |
Why?
|
| Breathing Exercises | 1 | 2017 | 8 | 0.550 |
Why?
|
| Aging | 5 | 2023 | 1254 | 0.550 |
Why?
|
| Drug Administration Schedule | 10 | 2018 | 749 | 0.540 |
Why?
|
| Health Status Disparities | 1 | 2020 | 252 | 0.540 |
Why?
|
| Yoga | 1 | 2017 | 13 | 0.540 |
Why?
|
| Metabolic Syndrome | 1 | 2021 | 365 | 0.540 |
Why?
|
| Health Status | 7 | 2022 | 408 | 0.530 |
Why?
|
| Delivery of Health Care | 5 | 2023 | 697 | 0.520 |
Why?
|
| Biomedical Research | 4 | 2023 | 554 | 0.520 |
Why?
|
| Phosphodiesterase 4 Inhibitors | 2 | 2013 | 5 | 0.510 |
Why?
|
| Dose-Response Relationship, Drug | 14 | 2015 | 1671 | 0.500 |
Why?
|
| Patient Discharge | 3 | 2021 | 511 | 0.500 |
Why?
|
| Psychological Techniques | 1 | 2016 | 8 | 0.500 |
Why?
|
| Cognitive Dysfunction | 1 | 2020 | 315 | 0.500 |
Why?
|
| Risk Factors | 23 | 2025 | 10945 | 0.490 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2023 | 659 | 0.480 |
Why?
|
| Young Adult | 18 | 2024 | 9966 | 0.470 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2018 | 767 | 0.470 |
Why?
|
| Respiratory Therapy | 4 | 2019 | 21 | 0.470 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2018 | 855 | 0.470 |
Why?
|
| Stress, Psychological | 2 | 2018 | 577 | 0.460 |
Why?
|
| Aminopyridines | 2 | 2013 | 55 | 0.460 |
Why?
|
| Retrospective Studies | 16 | 2025 | 17395 | 0.460 |
Why?
|
| Stroke | 2 | 2023 | 1082 | 0.460 |
Why?
|
| Randomized Controlled Trials as Topic | 11 | 2025 | 1249 | 0.460 |
Why?
|
| Depressive Disorder | 3 | 2017 | 481 | 0.450 |
Why?
|
| Benzamides | 2 | 2013 | 124 | 0.450 |
Why?
|
| Adolescent | 23 | 2024 | 20557 | 0.450 |
Why?
|
| Patient Participation | 1 | 2017 | 240 | 0.440 |
Why?
|
| Education, Medical, Continuing | 2 | 2012 | 144 | 0.430 |
Why?
|
| Physicians, Primary Care | 2 | 2012 | 97 | 0.430 |
Why?
|
| Cohort Studies | 14 | 2025 | 5176 | 0.430 |
Why?
|
| Ipratropium | 3 | 2011 | 7 | 0.430 |
Why?
|
| Allergens | 4 | 2025 | 276 | 0.430 |
Why?
|
| Needs Assessment | 3 | 2021 | 178 | 0.420 |
Why?
|
| Longitudinal Studies | 10 | 2025 | 1500 | 0.410 |
Why?
|
| Acute Disease | 10 | 2015 | 1163 | 0.400 |
Why?
|
| Patient Safety | 2 | 2017 | 442 | 0.400 |
Why?
|
| Aged, 80 and over | 16 | 2025 | 7138 | 0.390 |
Why?
|
| Fluticasone | 5 | 2023 | 15 | 0.390 |
Why?
|
| Patient Preference | 3 | 2020 | 141 | 0.380 |
Why?
|
| Leukocyte Count | 6 | 2025 | 249 | 0.380 |
Why?
|
| Prospective Studies | 15 | 2025 | 6568 | 0.380 |
Why?
|
| Health Care Costs | 3 | 2014 | 415 | 0.380 |
Why?
|
| Patient Reported Outcome Measures | 3 | 2025 | 213 | 0.380 |
Why?
|
| Time Factors | 12 | 2020 | 6451 | 0.380 |
Why?
|
| Recovery of Function | 3 | 2019 | 463 | 0.380 |
Why?
|
| Delayed-Action Preparations | 5 | 2020 | 122 | 0.370 |
Why?
|
| Influenza Vaccines | 3 | 2006 | 498 | 0.370 |
Why?
|
| Decision Making | 1 | 2017 | 699 | 0.360 |
Why?
|
| National Institute on Aging (U.S.) | 1 | 2011 | 3 | 0.360 |
Why?
|
| Respiration, Artificial | 5 | 2022 | 504 | 0.360 |
Why?
|
| Managed Care Programs | 1 | 2011 | 56 | 0.350 |
Why?
|
| Predictive Value of Tests | 9 | 2018 | 2314 | 0.350 |
Why?
|
| Interleukin-13 | 5 | 2024 | 94 | 0.350 |
Why?
|
| Bronchoconstriction | 2 | 2008 | 13 | 0.350 |
Why?
|
| Clinical Competence | 3 | 2012 | 1078 | 0.340 |
Why?
|
| Oxygen Inhalation Therapy | 3 | 2011 | 93 | 0.330 |
Why?
|
| Symptom Assessment | 2 | 2021 | 111 | 0.330 |
Why?
|
| Patient Education as Topic | 5 | 2020 | 462 | 0.330 |
Why?
|
| Smokers | 2 | 2022 | 44 | 0.330 |
Why?
|
| Health Resources | 1 | 2011 | 135 | 0.330 |
Why?
|
| Practice Guidelines as Topic | 6 | 2018 | 1307 | 0.320 |
Why?
|
| Pregnancy Complications | 2 | 2005 | 551 | 0.320 |
Why?
|
| Lung Diseases, Obstructive | 3 | 2007 | 27 | 0.320 |
Why?
|
| Prognosis | 8 | 2025 | 5016 | 0.320 |
Why?
|
| Adrenergic beta-Antagonists | 2 | 2010 | 223 | 0.320 |
Why?
|
| Evidence-Based Medicine | 5 | 2015 | 663 | 0.320 |
Why?
|
| Peak Expiratory Flow Rate | 5 | 2019 | 18 | 0.320 |
Why?
|
| Pulmonary Medicine | 3 | 2015 | 29 | 0.310 |
Why?
|
| Vitamin D | 1 | 2011 | 183 | 0.300 |
Why?
|
| Tomography, X-Ray Computed | 7 | 2025 | 2166 | 0.290 |
Why?
|
| Patient Selection | 4 | 2019 | 731 | 0.290 |
Why?
|
| Breath Tests | 3 | 2020 | 182 | 0.290 |
Why?
|
| Fungi | 2 | 2021 | 76 | 0.290 |
Why?
|
| Salmeterol Xinafoate | 7 | 2013 | 11 | 0.290 |
Why?
|
| Clinical Trials as Topic | 7 | 2023 | 1161 | 0.280 |
Why?
|
| Receptors, Adrenergic, beta-2 | 4 | 2011 | 56 | 0.280 |
Why?
|
| Respiratory System | 2 | 2022 | 98 | 0.280 |
Why?
|
| Clinical Decision-Making | 2 | 2021 | 306 | 0.280 |
Why?
|
| Guidelines as Topic | 1 | 2009 | 196 | 0.270 |
Why?
|
| Phytotherapy | 1 | 2007 | 50 | 0.270 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2017 | 3358 | 0.270 |
Why?
|
| Animals | 17 | 2025 | 34854 | 0.270 |
Why?
|
| Vasodilator Agents | 2 | 1998 | 208 | 0.270 |
Why?
|
| Signal Transduction | 7 | 2019 | 4720 | 0.260 |
Why?
|
| Antiviral Agents | 2 | 2023 | 823 | 0.260 |
Why?
|
| Socioeconomic Factors | 4 | 2025 | 902 | 0.260 |
Why?
|
| Injections, Subcutaneous | 4 | 2024 | 126 | 0.250 |
Why?
|
| Risk Assessment | 7 | 2020 | 3736 | 0.250 |
Why?
|
| Isoproterenol | 1 | 2006 | 97 | 0.250 |
Why?
|
| Activities of Daily Living | 3 | 2023 | 429 | 0.250 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2010 | 694 | 0.250 |
Why?
|
| Anti-Anxiety Agents | 3 | 2019 | 77 | 0.240 |
Why?
|
| Drug Delivery Systems | 2 | 2017 | 224 | 0.240 |
Why?
|
| Quality Improvement | 2 | 2025 | 700 | 0.240 |
Why?
|
| Bronchiectasis | 1 | 2025 | 22 | 0.230 |
Why?
|
| Age Factors | 9 | 2024 | 2923 | 0.230 |
Why?
|
| Bronchi | 2 | 2019 | 103 | 0.230 |
Why?
|
| 3',5'-Cyclic-AMP Phosphodiesterases | 1 | 2005 | 20 | 0.230 |
Why?
|
| Follow-Up Studies | 9 | 2025 | 5410 | 0.230 |
Why?
|
| Sex Factors | 4 | 2024 | 1354 | 0.230 |
Why?
|
| Patient Readmission | 2 | 2020 | 425 | 0.230 |
Why?
|
| Statistics, Nonparametric | 3 | 2017 | 437 | 0.230 |
Why?
|
| Nutrition Surveys | 3 | 2024 | 314 | 0.220 |
Why?
|
| Cross-Sectional Studies | 9 | 2024 | 3761 | 0.220 |
Why?
|
| Respiratory Mucosa | 1 | 2025 | 96 | 0.220 |
Why?
|
| Interleukin-4 | 3 | 2022 | 146 | 0.210 |
Why?
|
| Safety-net Providers | 1 | 2025 | 70 | 0.210 |
Why?
|
| Maintenance Chemotherapy | 2 | 2020 | 22 | 0.210 |
Why?
|
| Antidepressive Agents | 3 | 2019 | 327 | 0.210 |
Why?
|
| Expectorants | 2 | 2017 | 8 | 0.210 |
Why?
|
| General Practitioners | 1 | 2023 | 18 | 0.210 |
Why?
|
| Airway Remodeling | 2 | 2021 | 21 | 0.210 |
Why?
|
| Databases, Factual | 3 | 2025 | 1234 | 0.210 |
Why?
|
| Emphysema | 2 | 2016 | 67 | 0.210 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2025 | 143 | 0.210 |
Why?
|
| Hypoglycemic Agents | 2 | 2025 | 482 | 0.200 |
Why?
|
| Nasal Polyps | 1 | 2023 | 29 | 0.200 |
Why?
|
| Child | 11 | 2024 | 25783 | 0.200 |
Why?
|
| Polysomnography | 1 | 2024 | 155 | 0.200 |
Why?
|
| Doxycycline | 1 | 2023 | 121 | 0.200 |
Why?
|
| Rhinitis | 1 | 2023 | 43 | 0.200 |
Why?
|
| Frailty | 1 | 2025 | 136 | 0.190 |
Why?
|
| Dry Powder Inhalers | 2 | 2020 | 4 | 0.190 |
Why?
|
| Biological Factors | 1 | 2022 | 27 | 0.190 |
Why?
|
| Pulmonary Eosinophilia | 1 | 2022 | 7 | 0.190 |
Why?
|
| Vaccination | 2 | 2006 | 1018 | 0.190 |
Why?
|
| Administration, Oral | 3 | 2025 | 699 | 0.190 |
Why?
|
| Exhalation | 2 | 2020 | 12 | 0.190 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2025 | 1418 | 0.190 |
Why?
|
| Sinusitis | 1 | 2023 | 119 | 0.180 |
Why?
|
| Drug Overdose | 1 | 2022 | 73 | 0.180 |
Why?
|
| Magnesium Sulfate | 1 | 2022 | 51 | 0.180 |
Why?
|
| Respiratory Insufficiency | 2 | 2015 | 247 | 0.180 |
Why?
|
| Antimetabolites | 1 | 2021 | 30 | 0.180 |
Why?
|
| Sleep Wake Disorders | 1 | 2024 | 197 | 0.180 |
Why?
|
| Sexual and Gender Minorities | 1 | 2022 | 72 | 0.180 |
Why?
|
| Cytokines | 4 | 2023 | 1365 | 0.180 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2023 | 482 | 0.180 |
Why?
|
| Drug Monitoring | 2 | 2020 | 175 | 0.180 |
Why?
|
| Health Status Indicators | 2 | 2014 | 127 | 0.180 |
Why?
|
| Lung Diseases | 3 | 2025 | 408 | 0.170 |
Why?
|
| Data Interpretation, Statistical | 2 | 2020 | 229 | 0.170 |
Why?
|
| Salvage Therapy | 1 | 2023 | 200 | 0.170 |
Why?
|
| Immunity, Innate | 2 | 2021 | 413 | 0.170 |
Why?
|
| Respiratory System Agents | 1 | 2020 | 2 | 0.170 |
Why?
|
| Mental Status and Dementia Tests | 1 | 2020 | 24 | 0.170 |
Why?
|
| Protective Factors | 1 | 2021 | 90 | 0.170 |
Why?
|
| Smoking Cessation | 3 | 2008 | 191 | 0.170 |
Why?
|
| Biostatistics | 1 | 2020 | 14 | 0.170 |
Why?
|
| Time | 1 | 2020 | 99 | 0.170 |
Why?
|
| Aftercare | 1 | 2021 | 155 | 0.170 |
Why?
|
| Rhinitis, Allergic, Perennial | 1 | 2020 | 8 | 0.170 |
Why?
|
| Immune System | 2 | 2011 | 97 | 0.170 |
Why?
|
| Societies, Medical | 4 | 2023 | 778 | 0.170 |
Why?
|
| Medication Adherence | 4 | 2020 | 326 | 0.160 |
Why?
|
| Machine Learning | 1 | 2024 | 348 | 0.160 |
Why?
|
| Respiratory Physiological Phenomena | 1 | 2020 | 20 | 0.160 |
Why?
|
| Health Policy | 2 | 2020 | 232 | 0.160 |
Why?
|
| Home Care Services | 1 | 2020 | 75 | 0.160 |
Why?
|
| Odds Ratio | 3 | 2017 | 1255 | 0.160 |
Why?
|
| House Calls | 1 | 2020 | 38 | 0.160 |
Why?
|
| Equipment Design | 5 | 2020 | 600 | 0.160 |
Why?
|
| Blood Volume | 1 | 2020 | 81 | 0.160 |
Why?
|
| Patient Admission | 2 | 2018 | 187 | 0.160 |
Why?
|
| Biomarkers, Pharmacological | 1 | 2019 | 13 | 0.160 |
Why?
|
| Patient Care Management | 1 | 2020 | 66 | 0.160 |
Why?
|
| Cyclopropanes | 2 | 2013 | 71 | 0.160 |
Why?
|
| Insulin Resistance | 1 | 2025 | 698 | 0.160 |
Why?
|
| Sickness Impact Profile | 2 | 2011 | 39 | 0.150 |
Why?
|
| Receptors, Interleukin-5 | 1 | 2019 | 5 | 0.150 |
Why?
|
| Rewarming | 1 | 1999 | 12 | 0.150 |
Why?
|
| Receptors, Leukotriene | 1 | 2019 | 6 | 0.150 |
Why?
|
| Leukotrienes | 1 | 2019 | 8 | 0.150 |
Why?
|
| Critical Care | 3 | 2015 | 687 | 0.150 |
Why?
|
| Pharmaceutical Solutions | 1 | 2018 | 10 | 0.150 |
Why?
|
| Theophylline | 1 | 2018 | 24 | 0.150 |
Why?
|
| Respiration | 1 | 2019 | 123 | 0.150 |
Why?
|
| Hypothermia | 1 | 1999 | 66 | 0.150 |
Why?
|
| Ozone | 1 | 1998 | 19 | 0.150 |
Why?
|
| Walking | 1 | 2020 | 233 | 0.150 |
Why?
|
| Pulmonologists | 1 | 2018 | 5 | 0.140 |
Why?
|
| Health Services | 2 | 2016 | 71 | 0.140 |
Why?
|
| Renal Replacement Therapy | 1 | 2020 | 158 | 0.140 |
Why?
|
| Respiratory Mechanics | 2 | 2017 | 78 | 0.140 |
Why?
|
| Receptors, Interleukin-13 | 1 | 2018 | 4 | 0.140 |
Why?
|
| Receptors, Interleukin-4 | 1 | 2018 | 11 | 0.140 |
Why?
|
| Cysteine | 1 | 2019 | 142 | 0.140 |
Why?
|
| Emergency Service, Hospital | 4 | 2022 | 1170 | 0.140 |
Why?
|
| Exercise Test | 2 | 2016 | 256 | 0.140 |
Why?
|
| Diagnosis, Differential | 5 | 2016 | 1966 | 0.140 |
Why?
|
| Logistic Models | 4 | 2022 | 1841 | 0.140 |
Why?
|
| Frail Elderly | 2 | 2025 | 107 | 0.140 |
Why?
|
| Calcitonin | 1 | 2017 | 32 | 0.140 |
Why?
|
| Community Health Services | 1 | 2018 | 92 | 0.140 |
Why?
|
| Health Services Needs and Demand | 1 | 2019 | 181 | 0.140 |
Why?
|
| Radiation Injuries | 1 | 2019 | 158 | 0.140 |
Why?
|
| Models, Statistical | 1 | 2020 | 495 | 0.140 |
Why?
|
| Hypnotics and Sedatives | 1 | 2019 | 137 | 0.140 |
Why?
|
| Lung Injury | 1 | 2019 | 123 | 0.140 |
Why?
|
| Patient Care Team | 1 | 2021 | 576 | 0.130 |
Why?
|
| Immunologic Factors | 1 | 2018 | 185 | 0.130 |
Why?
|
| Drug Tolerance | 1 | 2017 | 40 | 0.130 |
Why?
|
| Critical Pathways | 1 | 2017 | 75 | 0.130 |
Why?
|
| Pharmacogenetics | 1 | 2018 | 200 | 0.130 |
Why?
|
| Air Pollutants | 1 | 1998 | 114 | 0.130 |
Why?
|
| Diaphragm | 1 | 2017 | 98 | 0.130 |
Why?
|
| Resuscitation | 1 | 1999 | 270 | 0.130 |
Why?
|
| Drug Design | 1 | 2017 | 161 | 0.130 |
Why?
|
| Staphylococcus aureus | 1 | 2020 | 479 | 0.120 |
Why?
|
| Chronic Disease | 4 | 2025 | 1233 | 0.120 |
Why?
|
| Referral and Consultation | 1 | 2020 | 570 | 0.120 |
Why?
|
| Quinolones | 2 | 2013 | 58 | 0.120 |
Why?
|
| Beclomethasone | 1 | 1995 | 1 | 0.120 |
Why?
|
| Pregnenediones | 1 | 1995 | 1 | 0.120 |
Why?
|
| Adaptation, Psychological | 1 | 2019 | 455 | 0.120 |
Why?
|
| Sleep Medicine Specialty | 1 | 2015 | 8 | 0.120 |
Why?
|
| Indans | 2 | 2013 | 54 | 0.120 |
Why?
|
| Blood Proteins | 1 | 2016 | 136 | 0.120 |
Why?
|
| Mental Health | 1 | 2019 | 377 | 0.120 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2017 | 210 | 0.120 |
Why?
|
| Health Education | 1 | 2017 | 235 | 0.120 |
Why?
|
| Marijuana Smoking | 1 | 2015 | 32 | 0.120 |
Why?
|
| Inflammation Mediators | 1 | 2017 | 241 | 0.120 |
Why?
|
| Self Care | 1 | 2017 | 227 | 0.120 |
Why?
|
| Prostaglandins | 2 | 2022 | 43 | 0.120 |
Why?
|
| Social Support | 1 | 2018 | 386 | 0.120 |
Why?
|
| Fatigue | 2 | 2016 | 201 | 0.120 |
Why?
|
| Obesity | 2 | 2017 | 2398 | 0.120 |
Why?
|
| Cannabis | 1 | 2015 | 49 | 0.110 |
Why?
|
| Hypertension, Pulmonary | 1 | 2020 | 463 | 0.110 |
Why?
|
| Population Surveillance | 2 | 2022 | 416 | 0.110 |
Why?
|
| Aspergillus fumigatus | 1 | 2015 | 44 | 0.110 |
Why?
|
| Aspergillosis, Allergic Bronchopulmonary | 1 | 2015 | 17 | 0.110 |
Why?
|
| Area Under Curve | 3 | 2014 | 321 | 0.110 |
Why?
|
| Chemokine CCL26 | 2 | 2025 | 2 | 0.110 |
Why?
|
| Health Behavior | 1 | 2018 | 398 | 0.110 |
Why?
|
| Drug Resistance | 2 | 2013 | 252 | 0.110 |
Why?
|
| Psychometrics | 3 | 2015 | 693 | 0.110 |
Why?
|
| Sex Distribution | 2 | 2017 | 327 | 0.110 |
Why?
|
| Models, Theoretical | 1 | 2017 | 391 | 0.110 |
Why?
|
| Bronchitis | 2 | 2011 | 33 | 0.110 |
Why?
|
| Patient Satisfaction | 1 | 2018 | 482 | 0.110 |
Why?
|
| Age Distribution | 2 | 2017 | 437 | 0.110 |
Why?
|
| Patient Outcome Assessment | 1 | 2014 | 94 | 0.110 |
Why?
|
| Age of Onset | 2 | 2016 | 626 | 0.110 |
Why?
|
| Kv1.3 Potassium Channel | 1 | 2014 | 38 | 0.110 |
Why?
|
| Personnel, Hospital | 1 | 1994 | 33 | 0.110 |
Why?
|
| Reproducibility of Results | 2 | 2018 | 3018 | 0.110 |
Why?
|
| Triazoles | 1 | 2015 | 147 | 0.110 |
Why?
|
| Ambroxol | 2 | 2017 | 4 | 0.100 |
Why?
|
| Pandemics | 1 | 2021 | 1186 | 0.100 |
Why?
|
| Tuberculosis, Osteoarticular | 1 | 1993 | 4 | 0.100 |
Why?
|
| Vitamin D Deficiency | 2 | 2013 | 74 | 0.100 |
Why?
|
| Mucociliary Clearance | 1 | 2013 | 5 | 0.100 |
Why?
|
| Caregivers | 2 | 2023 | 596 | 0.100 |
Why?
|
| Tuberculosis, Lymph Node | 1 | 1993 | 20 | 0.100 |
Why?
|
| Chi-Square Distribution | 2 | 2011 | 588 | 0.100 |
Why?
|
| Bone Density | 1 | 1995 | 370 | 0.100 |
Why?
|
| Hospital Costs | 2 | 2011 | 187 | 0.100 |
Why?
|
| Electric Stimulation Therapy | 1 | 2013 | 84 | 0.100 |
Why?
|
| Educational Measurement | 2 | 2012 | 329 | 0.100 |
Why?
|
| Receptors, G-Protein-Coupled | 2 | 2012 | 304 | 0.100 |
Why?
|
| Survival Rate | 1 | 2017 | 2196 | 0.100 |
Why?
|
| Noninvasive Ventilation | 1 | 2013 | 33 | 0.100 |
Why?
|
| Receptors, Prostaglandin E, EP4 Subtype | 1 | 2012 | 7 | 0.090 |
Why?
|
| Case-Control Studies | 5 | 2019 | 3414 | 0.090 |
Why?
|
| Antifungal Agents | 1 | 2015 | 314 | 0.090 |
Why?
|
| Drugs, Investigational | 1 | 2012 | 24 | 0.090 |
Why?
|
| Peroxisome Proliferator-Activated Receptors | 1 | 2011 | 11 | 0.090 |
Why?
|
| Histone Deacetylase 2 | 1 | 2011 | 14 | 0.090 |
Why?
|
| Length of Stay | 3 | 2013 | 1382 | 0.090 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2014 | 277 | 0.090 |
Why?
|
| Bronchography | 1 | 2011 | 6 | 0.090 |
Why?
|
| Electrocardiography | 2 | 2012 | 996 | 0.090 |
Why?
|
| Health Promotion | 1 | 2015 | 399 | 0.090 |
Why?
|
| Pyruvic Acid | 1 | 2011 | 38 | 0.090 |
Why?
|
| Oxygen | 1 | 2015 | 569 | 0.090 |
Why?
|
| Psychology | 1 | 2011 | 58 | 0.090 |
Why?
|
| Attitude of Health Personnel | 1 | 2017 | 725 | 0.090 |
Why?
|
| Multivariate Analysis | 4 | 2017 | 1444 | 0.090 |
Why?
|
| Albuterol, Ipratropium Drug Combination | 1 | 2011 | 2 | 0.090 |
Why?
|
| Emergency Medical Services | 2 | 2013 | 416 | 0.090 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2020 | 846 | 0.090 |
Why?
|
| HIV Infections | 2 | 2022 | 2049 | 0.090 |
Why?
|
| Respiratory Tract Diseases | 1 | 2011 | 80 | 0.090 |
Why?
|
| Italy | 2 | 2022 | 130 | 0.090 |
Why?
|
| Proportional Hazards Models | 2 | 2014 | 1461 | 0.090 |
Why?
|
| Rest | 1 | 2011 | 66 | 0.090 |
Why?
|
| Palliative Care | 1 | 2015 | 456 | 0.090 |
Why?
|
| Veterans | 1 | 2022 | 1763 | 0.080 |
Why?
|
| Osteomyelitis | 1 | 1993 | 213 | 0.080 |
Why?
|
| Cross-Over Studies | 2 | 2004 | 326 | 0.080 |
Why?
|
| Developing Countries | 1 | 2012 | 303 | 0.080 |
Why?
|
| Observation | 1 | 2010 | 43 | 0.080 |
Why?
|
| Isomerism | 1 | 2010 | 26 | 0.080 |
Why?
|
| Propranolol | 1 | 2010 | 112 | 0.080 |
Why?
|
| Bronchoscopy | 1 | 2011 | 174 | 0.080 |
Why?
|
| Propensity Score | 1 | 2011 | 255 | 0.080 |
Why?
|
| Drug Therapy | 1 | 2010 | 87 | 0.080 |
Why?
|
| Bayes Theorem | 2 | 2022 | 312 | 0.080 |
Why?
|
| Body Mass Index | 3 | 2025 | 1700 | 0.080 |
Why?
|
| Respiratory Hypersensitivity | 1 | 2010 | 51 | 0.080 |
Why?
|
| Proteins | 2 | 2014 | 1038 | 0.080 |
Why?
|
| Powders | 2 | 2008 | 24 | 0.080 |
Why?
|
| Vibration | 1 | 2008 | 29 | 0.070 |
Why?
|
| Immunity | 1 | 2009 | 183 | 0.070 |
Why?
|
| Lymphocytes | 2 | 2021 | 364 | 0.070 |
Why?
|
| Sensitivity and Specificity | 4 | 2014 | 2139 | 0.070 |
Why?
|
| Catheter Ablation | 1 | 2011 | 257 | 0.070 |
Why?
|
| Internet | 1 | 2011 | 406 | 0.070 |
Why?
|
| Justicia | 1 | 2007 | 3 | 0.070 |
Why?
|
| Tylophora | 1 | 2007 | 3 | 0.070 |
Why?
|
| Picrorhiza | 1 | 2007 | 3 | 0.070 |
Why?
|
| Minority Groups | 2 | 2022 | 250 | 0.070 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2008 | 91 | 0.070 |
Why?
|
| Endopeptidases | 1 | 2008 | 114 | 0.070 |
Why?
|
| Stilbenes | 1 | 2007 | 38 | 0.070 |
Why?
|
| Curcumin | 1 | 2007 | 43 | 0.070 |
Why?
|
| Half-Life | 1 | 2007 | 161 | 0.070 |
Why?
|
| Pulmonary Alveoli | 1 | 2008 | 141 | 0.070 |
Why?
|
| Heart Rate | 2 | 2008 | 584 | 0.070 |
Why?
|
| Morbidity | 1 | 2007 | 256 | 0.060 |
Why?
|
| Remission Induction | 2 | 2024 | 306 | 0.060 |
Why?
|
| Aerosols | 2 | 2017 | 64 | 0.060 |
Why?
|
| Medicare | 2 | 2020 | 447 | 0.060 |
Why?
|
| Endocytosis | 1 | 2006 | 126 | 0.060 |
Why?
|
| Energy Metabolism | 1 | 2011 | 784 | 0.060 |
Why?
|
| History, 21st Century | 1 | 2007 | 271 | 0.060 |
Why?
|
| Incidence | 4 | 2017 | 3376 | 0.060 |
Why?
|
| Chemokine CCL17 | 1 | 2025 | 10 | 0.060 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2007 | 305 | 0.060 |
Why?
|
| Recurrence | 3 | 2015 | 1453 | 0.060 |
Why?
|
| Single-Blind Method | 3 | 2008 | 242 | 0.060 |
Why?
|
| Disease Models, Animal | 2 | 2014 | 4690 | 0.060 |
Why?
|
| Treatment Failure | 1 | 2006 | 364 | 0.060 |
Why?
|
| Nucleotides, Cyclic | 1 | 2005 | 7 | 0.060 |
Why?
|
| History, 20th Century | 1 | 2007 | 385 | 0.060 |
Why?
|
| Vaccines, Inactivated | 1 | 2006 | 148 | 0.060 |
Why?
|
| Cyclohexanecarboxylic Acids | 1 | 2005 | 17 | 0.060 |
Why?
|
| Survival Analysis | 3 | 2014 | 1574 | 0.060 |
Why?
|
| Cyclic Nucleotide Phosphodiesterases, Type 4 | 1 | 2005 | 11 | 0.060 |
Why?
|
| Secondary Prevention | 1 | 2006 | 219 | 0.060 |
Why?
|
| Infant | 1 | 2020 | 13049 | 0.060 |
Why?
|
| Ontario | 2 | 1997 | 90 | 0.060 |
Why?
|
| Carboxylic Acids | 1 | 2005 | 26 | 0.060 |
Why?
|
| Focus Groups | 2 | 2020 | 223 | 0.060 |
Why?
|
| Phosphoric Diester Hydrolases | 1 | 2005 | 69 | 0.060 |
Why?
|
| Cystic Fibrosis | 1 | 2007 | 264 | 0.060 |
Why?
|
| Equipment and Supplies | 1 | 2005 | 28 | 0.060 |
Why?
|
| Methacholine Chloride | 2 | 2009 | 16 | 0.060 |
Why?
|
| Amides | 1 | 2005 | 91 | 0.060 |
Why?
|
| Unsupervised Machine Learning | 1 | 2024 | 14 | 0.050 |
Why?
|
| Blood Pressure | 2 | 2008 | 1402 | 0.050 |
Why?
|
| Program Development | 1 | 2025 | 191 | 0.050 |
Why?
|
| Nitriles | 1 | 2005 | 155 | 0.050 |
Why?
|
| Interviews as Topic | 2 | 2020 | 425 | 0.050 |
Why?
|
| Receptors, Muscarinic | 1 | 2024 | 12 | 0.050 |
Why?
|
| Canada | 2 | 2015 | 337 | 0.050 |
Why?
|
| Neoplasms | 1 | 2019 | 2961 | 0.050 |
Why?
|
| Receptors, Glucocorticoid | 1 | 2004 | 106 | 0.050 |
Why?
|
| Cough | 2 | 2016 | 96 | 0.050 |
Why?
|
| Linear Models | 3 | 2016 | 714 | 0.050 |
Why?
|
| Infusions, Intravenous | 2 | 2011 | 547 | 0.050 |
Why?
|
| Mass Screening | 1 | 2010 | 830 | 0.050 |
Why?
|
| Safety | 1 | 2004 | 216 | 0.050 |
Why?
|
| Indoles | 1 | 2005 | 201 | 0.050 |
Why?
|
| Obstetric Labor Complications | 1 | 2004 | 99 | 0.050 |
Why?
|
| Societies | 1 | 2023 | 27 | 0.050 |
Why?
|
| Placebos | 1 | 2004 | 235 | 0.050 |
Why?
|
| Lung Volume Measurements | 1 | 2003 | 85 | 0.050 |
Why?
|
| United States Food and Drug Administration | 1 | 2024 | 160 | 0.050 |
Why?
|
| Antibody Formation | 1 | 2004 | 274 | 0.050 |
Why?
|
| Texas | 2 | 2025 | 3632 | 0.050 |
Why?
|
| Cluster Analysis | 1 | 2024 | 431 | 0.050 |
Why?
|
| Anti-Glomerular Basement Membrane Disease | 1 | 2002 | 8 | 0.050 |
Why?
|
| Pilot Projects | 1 | 2007 | 1444 | 0.050 |
Why?
|
| Antibodies, Antineutrophil Cytoplasmic | 1 | 2002 | 30 | 0.050 |
Why?
|
| Ambulatory Care | 2 | 1997 | 412 | 0.050 |
Why?
|
| Advisory Committees | 1 | 2023 | 151 | 0.050 |
Why?
|
| Health Surveys | 2 | 2018 | 260 | 0.050 |
Why?
|
| Homosexuality, Male | 1 | 2022 | 72 | 0.050 |
Why?
|
| Patients | 1 | 2023 | 129 | 0.050 |
Why?
|
| Vasculitis | 1 | 2002 | 50 | 0.050 |
Why?
|
| Glomerulonephritis | 1 | 2002 | 74 | 0.050 |
Why?
|
| Antigens, Viral | 1 | 2004 | 439 | 0.050 |
Why?
|
| Pregnancy | 2 | 2005 | 7557 | 0.050 |
Why?
|
| Intensive Care Units | 2 | 2016 | 524 | 0.050 |
Why?
|
| Educational Status | 1 | 2023 | 294 | 0.050 |
Why?
|
| Research Design | 2 | 2020 | 743 | 0.050 |
Why?
|
| Biological Availability | 1 | 2002 | 143 | 0.050 |
Why?
|
| Lymphoma, AIDS-Related | 1 | 2002 | 35 | 0.050 |
Why?
|
| Adenosine Monophosphate | 1 | 2021 | 42 | 0.040 |
Why?
|
| Consensus | 1 | 2024 | 658 | 0.040 |
Why?
|
| Costs and Cost Analysis | 1 | 2022 | 166 | 0.040 |
Why?
|
| Apoptosis | 1 | 2008 | 1901 | 0.040 |
Why?
|
| Steroids | 1 | 2022 | 174 | 0.040 |
Why?
|
| Antigens, Fungal | 1 | 2021 | 34 | 0.040 |
Why?
|
| Neutrophils | 1 | 2023 | 360 | 0.040 |
Why?
|
| Alanine | 1 | 2021 | 158 | 0.040 |
Why?
|
| Benzoxazines | 1 | 2020 | 24 | 0.040 |
Why?
|
| Sleep | 1 | 2024 | 373 | 0.040 |
Why?
|
| Diet | 1 | 2007 | 1125 | 0.040 |
Why?
|
| Receptors, Interleukin-4, Type II | 1 | 2020 | 1 | 0.040 |
Why?
|
| Lung Diseases, Interstitial | 1 | 2002 | 175 | 0.040 |
Why?
|
| Gene Expression | 2 | 2020 | 1563 | 0.040 |
Why?
|
| Pragmatic Clinical Trials as Topic | 1 | 2020 | 41 | 0.040 |
Why?
|
| Datasets as Topic | 1 | 2020 | 105 | 0.040 |
Why?
|
| Enterotoxins | 1 | 2020 | 82 | 0.040 |
Why?
|
| Markov Chains | 1 | 2020 | 101 | 0.040 |
Why?
|
| Maximal Expiratory Flow Rate | 1 | 2019 | 2 | 0.040 |
Why?
|
| Specialization | 1 | 2020 | 80 | 0.040 |
Why?
|
| Radiation Pneumonitis | 1 | 2019 | 10 | 0.040 |
Why?
|
| Tremor | 2 | 2013 | 136 | 0.040 |
Why?
|
| Choice Behavior | 1 | 2020 | 135 | 0.040 |
Why?
|
| Bronchial Provocation Tests | 1 | 1998 | 12 | 0.040 |
Why?
|
| Alprostadil | 1 | 1998 | 22 | 0.040 |
Why?
|
| Pulmonary Wedge Pressure | 1 | 1998 | 51 | 0.040 |
Why?
|
| Drug Compounding | 1 | 2018 | 42 | 0.040 |
Why?
|
| Anti-HIV Agents | 1 | 2002 | 347 | 0.040 |
Why?
|
| Epoprostenol | 1 | 1998 | 44 | 0.040 |
Why?
|
| Self-Management | 1 | 2020 | 105 | 0.040 |
Why?
|
| Skin Tests | 1 | 1998 | 80 | 0.040 |
Why?
|
| Pulmonary Fibrosis | 1 | 2019 | 112 | 0.030 |
Why?
|
| Total Lung Capacity | 1 | 2017 | 13 | 0.030 |
Why?
|
| Functional Residual Capacity | 1 | 2017 | 15 | 0.030 |
Why?
|
| Iowa | 1 | 2017 | 13 | 0.030 |
Why?
|
| Carbocysteine | 1 | 2017 | 1 | 0.030 |
Why?
|
| Thioglycolates | 1 | 2017 | 12 | 0.030 |
Why?
|
| Respiratory Tract Infections | 2 | 2013 | 291 | 0.030 |
Why?
|
| Oxygen Consumption | 1 | 1998 | 304 | 0.030 |
Why?
|
| Metabolome | 1 | 2020 | 324 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 2020 | 576 | 0.030 |
Why?
|
| Genetic Variation | 1 | 2004 | 1580 | 0.030 |
Why?
|
| Metformin | 1 | 2019 | 166 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 1998 | 396 | 0.030 |
Why?
|
| Computer Simulation | 1 | 2020 | 701 | 0.030 |
Why?
|
| Thiophenes | 1 | 2017 | 69 | 0.030 |
Why?
|
| Immunosenescence | 1 | 2016 | 4 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 2017 | 277 | 0.030 |
Why?
|
| Hospital Mortality | 1 | 2022 | 1081 | 0.030 |
Why?
|
| Acetylcysteine | 1 | 2017 | 82 | 0.030 |
Why?
|
| Physical Endurance | 1 | 2016 | 45 | 0.030 |
Why?
|
| ABO Blood-Group System | 1 | 2016 | 66 | 0.030 |
Why?
|
| Tissue Distribution | 1 | 2017 | 380 | 0.030 |
Why?
|
| Pulmonary Surfactant-Associated Protein D | 1 | 2016 | 9 | 0.030 |
Why?
|
| Chemokines, CC | 1 | 2016 | 27 | 0.030 |
Why?
|
| Risk | 1 | 2018 | 761 | 0.030 |
Why?
|
| Uteroglobin | 1 | 2016 | 41 | 0.030 |
Why?
|
| Interleukins | 1 | 2017 | 129 | 0.030 |
Why?
|
| Statistics as Topic | 1 | 2016 | 254 | 0.030 |
Why?
|
| Adrenal Glands | 1 | 1995 | 46 | 0.030 |
Why?
|
| Adrenocorticotropic Hormone | 1 | 1995 | 74 | 0.030 |
Why?
|
| Osteocalcin | 1 | 1995 | 46 | 0.030 |
Why?
|
| In Vitro Techniques | 1 | 2017 | 862 | 0.030 |
Why?
|
| Anxiety Disorders | 1 | 2022 | 734 | 0.030 |
Why?
|
| Fibrinogen | 1 | 2016 | 157 | 0.030 |
Why?
|
| Quantitative Trait Loci | 1 | 2016 | 313 | 0.030 |
Why?
|
| Hydrocortisone | 1 | 1995 | 226 | 0.030 |
Why?
|
| Congresses as Topic | 1 | 2015 | 186 | 0.030 |
Why?
|
| Insulin | 1 | 2019 | 1168 | 0.030 |
Why?
|
| Ovalbumin | 1 | 2014 | 123 | 0.030 |
Why?
|
| Rats, Inbred F344 | 1 | 2014 | 94 | 0.030 |
Why?
|
| Potassium Channel Blockers | 1 | 2014 | 84 | 0.030 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 2014 | 149 | 0.030 |
Why?
|
| Ethiopia | 1 | 1993 | 21 | 0.030 |
Why?
|
| Reference Values | 1 | 2014 | 703 | 0.030 |
Why?
|
| Bone and Bones | 1 | 1995 | 301 | 0.030 |
Why?
|
| Medical Staff, Hospital | 1 | 1994 | 98 | 0.030 |
Why?
|
| Radionuclide Imaging | 1 | 1993 | 144 | 0.030 |
Why?
|
| Nasopharyngitis | 1 | 2013 | 5 | 0.030 |
Why?
|
| Physical Exertion | 1 | 2013 | 73 | 0.030 |
Why?
|
| Intubation, Intratracheal | 1 | 2016 | 288 | 0.020 |
Why?
|
| Nursing Staff, Hospital | 1 | 1994 | 70 | 0.020 |
Why?
|
| Spasm | 1 | 2013 | 48 | 0.020 |
Why?
|
| C-Reactive Protein | 1 | 2016 | 464 | 0.020 |
Why?
|
| Ribs | 1 | 1993 | 54 | 0.020 |
Why?
|
| Emigration and Immigration | 1 | 1993 | 83 | 0.020 |
Why?
|
| Tachycardia | 1 | 2013 | 68 | 0.020 |
Why?
|
| Psychomotor Performance | 1 | 1994 | 182 | 0.020 |
Why?
|
| Interleukin-10 | 1 | 2014 | 188 | 0.020 |
Why?
|
| Immunologic Memory | 1 | 2014 | 199 | 0.020 |
Why?
|
| Internal Medicine | 1 | 1994 | 156 | 0.020 |
Why?
|
| Headache | 1 | 2013 | 110 | 0.020 |
Why?
|
| Models, Biological | 1 | 2017 | 1445 | 0.020 |
Why?
|
| Hospitals | 1 | 1995 | 439 | 0.020 |
Why?
|
| Potassium | 1 | 2013 | 275 | 0.020 |
Why?
|
| Principal Component Analysis | 1 | 2012 | 157 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2014 | 802 | 0.020 |
Why?
|
| Education | 1 | 2012 | 111 | 0.020 |
Why?
|
| Perception | 1 | 2013 | 236 | 0.020 |
Why?
|
| Radioactive Tracers | 1 | 2011 | 20 | 0.020 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2011 | 53 | 0.020 |
Why?
|
| Observer Variation | 1 | 2012 | 306 | 0.020 |
Why?
|
| Medical History Taking | 1 | 2011 | 114 | 0.020 |
Why?
|
| Glycolysis | 1 | 2011 | 165 | 0.020 |
Why?
|
| Radiography | 1 | 1993 | 818 | 0.020 |
Why?
|
| Carbon Isotopes | 1 | 2011 | 233 | 0.020 |
Why?
|
| Drug Inverse Agonism | 1 | 2010 | 3 | 0.020 |
Why?
|
| Physical Examination | 1 | 2011 | 165 | 0.020 |
Why?
|
| Bronchial Hyperreactivity | 1 | 2010 | 34 | 0.020 |
Why?
|
| Multicenter Studies as Topic | 1 | 2011 | 312 | 0.020 |
Why?
|
| Genotype | 1 | 2016 | 2703 | 0.020 |
Why?
|
| Health Care Surveys | 1 | 2011 | 295 | 0.020 |
Why?
|
| Lymphoma | 1 | 1993 | 331 | 0.020 |
Why?
|
| Ligands | 1 | 2011 | 495 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2011 | 796 | 0.020 |
Why?
|
| Alprenolol | 1 | 2009 | 2 | 0.020 |
Why?
|
| Bronchoconstrictor Agents | 1 | 2009 | 8 | 0.020 |
Why?
|
| Program Evaluation | 1 | 2011 | 456 | 0.020 |
Why?
|
| Genome-Wide Association Study | 1 | 2016 | 1831 | 0.020 |
Why?
|
| Blood Glucose | 1 | 2013 | 1121 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2011 | 881 | 0.020 |
Why?
|
| Pulmonary Surfactants | 1 | 2008 | 46 | 0.020 |
Why?
|
| Stereoisomerism | 1 | 2008 | 119 | 0.020 |
Why?
|
| Interleukin-6 | 1 | 2009 | 435 | 0.020 |
Why?
|
| ROC Curve | 1 | 2009 | 600 | 0.020 |
Why?
|
| Rats | 1 | 2014 | 3607 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2016 | 2851 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2009 | 666 | 0.020 |
Why?
|
| beta-Adrenergic Receptor Kinases | 1 | 2006 | 11 | 0.020 |
Why?
|
| Arrestins | 1 | 2006 | 25 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2009 | 1050 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2006 | 424 | 0.020 |
Why?
|
| Epinephrine | 1 | 2006 | 155 | 0.010 |
Why?
|
| Prednisone | 1 | 2006 | 253 | 0.010 |
Why?
|
| Protein Transport | 1 | 2006 | 370 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 2014 | 1757 | 0.010 |
Why?
|
| Myocardial Ischemia | 1 | 2008 | 341 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2006 | 826 | 0.010 |
Why?
|
| Epithelial Cells | 1 | 2009 | 906 | 0.010 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2008 | 479 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2006 | 1008 | 0.010 |
Why?
|
| Child, Preschool | 2 | 2012 | 14736 | 0.010 |
Why?
|
| Internship and Residency | 1 | 1994 | 1258 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2006 | 1612 | 0.010 |
Why?
|
| Causality | 1 | 2002 | 94 | 0.010 |
Why?
|
| Lymphoma, B-Cell | 1 | 2002 | 148 | 0.010 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2002 | 153 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2009 | 4758 | 0.010 |
Why?
|
| Maximal Midexpiratory Flow Rate | 1 | 1996 | 3 | 0.010 |
Why?
|
| Electronics, Medical | 1 | 1996 | 9 | 0.010 |
Why?
|
| Monitoring, Physiologic | 1 | 1998 | 377 | 0.010 |
Why?
|
| Bias | 1 | 1996 | 144 | 0.010 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 1996 | 131 | 0.010 |
Why?
|
| Mice | 1 | 2009 | 18509 | 0.010 |
Why?
|
| Algorithms | 1 | 1998 | 1725 | 0.010 |
Why?
|